Statins have side effects. Reducing your cholesterol levels does not extend your life. Anti-inflammatories can. Despite the advertising that tells us how aspirin saves lives, aspirin and NSAIDS kill at least 20,000 people a year. [www.gordonresearch.com/articles_acam/acam_response_cranton_rebuttal_5-15-03.html] They either bleed to death or die from hemorrhagic strokes. The total number of deaths due to bleeding caused by the use of NSAIDS is over 30,000 a year. Coumadin? From the 2001 Encarta Encyclopedia we see:
Possible side effects of [Coumadin] include hemorrhage (severe bleeding), chest pain, joint pain, headache, difficulty breathing, difficulty swallowing, or swelling. Other side effects may include diarrhea, nausea, fever, hair loss, skin inflammation, discolored (purplish) toes, or gangrene. Excessive bleeding from a nosebleed, cut, puncture, or unusual menstrual flow should be checked by a doctor.
Just recently, medical journals are pointing out that patients on coumadin for a long period of time increase their chances of hemorrhagic strokes.
No wonder it’s the main ingredient in rat poison.
According to Dr Gordon, most of the blood in blood banks is used to replace the blood lost by people on conventional blood thinners. Does this tell you anything?
We dispute the practice of using aspirin as a blood thinner throughout our articles on cardiovascular disease, but right here we will give you Dr Val Fuster’s take on aspirin (and other anticoagulants) because aspirin (and the others) affect only one pathway to coagulation:
Aspirin interferes with only one of the three pathways of platelet activation – the one dependent on thromboxane A. The other two pathways — one dependent on ADP and collagen and the other on thrombin — remain unaffected, as does the coagulation system. On the other hand, current anticoagulant agents interfere only partially with the coagulation system and do not affect platelet activation. It is not surprising, therefore, that aspirin or anticoagulants cannot completely prevent coronary thrombotic events, although the relative antithrombotic effectiveness of both types of antithrombotic agents is clinically similar.